このエントリーをはてなブックマークに追加
ID 18021
Eprint ID
18021
フルテキストURL
Thumnail 82_575.pdf 2.57 MB
タイトル(別表記)
Treatment of Lung Cancer with Bleomycin -Its Evaluation and Prevention of Side Effects-
著者
木村 郁郎 岡山大学医学部平木内科
木畑 正義 岡山大学医学部平木内科
半沢 敦正 岡山大学医学部平木内科
守谷 欣明 岡山大学医学部平木内科
大熨 泰亮 岡山大学医学部平木内科
高田 宏美 岡山大学医学部平木内科
西崎 良知 岡山大学医学部平木内科
国政 郁哉 岡山大学医学部平木内科
西下 明 岡山大学医学部平木内科
谷崎 勝朗 岡山大学医学部平木内科
高野 純行 岡山大学医学部平木内科
抄録
Bleomycin was administered to 35 patients with lung cancer (primary lung cancer in 28 cases, metastatic lung cancer in 7 cases), and produced following results. Fibroblast-inhibiting agents were simultaneously administered as multiple combination therapy, "CPBP", with chloroquine, phytonadione, Bleomycin and prednisolone. In consequence, beneficial effect was seen in a fairly large number of cases including small sized lung cancer and terminal cancer cases. In comparison with other antineoplastic agents, Bleomycin had the advantage of not causing hematopoietic disturbances in host. It is considered, however, that the therapeutic efficacy of Bleomycin above mentioned can not be evaluated without prevention of its side effects. Of 67 cases given Bleomycin treatment 10 cases showed fever and 8 cases lung disturbances. Among these side effects lung distur bances rather than hematopoietic disturbances should be kept in mind. In 44 cases of cancer patients who were treated with combination of Blcomycin and a fibroblast-inhibiting agent, chloroquine, lung disturbances were seen in only 4 of them. On the other hand, in 12 cases of malignant lymphoma which were treated without the combined therapy, 4 of them showed lung disturbances-a high rate pulmonary complications than in cancer. In an experimental study of combination of Bleomycin and dextran sulfate inhibition of lung disturbances was observed histologically. And an increase of α and β globulin, triglyceride, seromucoid and fibrinogen was depressed by this combination therapy. This combination therapy also inhibited metastasis by intravenous inoculation of Ehrlich ascites tumor cell in lungs impaired by administration of Bleomycin. It is important that an effective method of preventing side effects of Bleomycin is established so that enough dose of the drug can be admistered.
発行日
1970-12-30
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
82巻
11-12号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
575
終了ページ
584
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/82/11-12/82_11-12_561/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/
言語
Japanese
OAI-PMH Set
岡山大学
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Sort Key
14
Eprints Journal Name
joma